Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

Big Pharma’s Experts Go to Biotech

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca. Vo...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...

AstraZeneca and Ironwood’s IBS-C Drug Approved in China

Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults with the condition. The good news coincides with big chang...

Shake-up in AstraZeneca

British pharma giant has aligned therapy R&D units to new commercial strategy and hired oncology expert Jose Baselga to lead new phase in development. AstraZeneca has announced a major shake-up...

Flu Vaccines Effectiveness Research

The quadrivalent live attenuated influenza vaccine (LAIV4) is less effective than inactivated influenza vaccine (IIV) against influenza A/H1N1pdm09 in all pediatric age groups, according to research p...

NICE Recommends AstraZeneca’s Asthma Treatment

NICE has recommended the use of AstraZeneca’s severe asthma treatment Faserna (benralizumab) after the company revised its initial pricing offer. The recommendation from England's cost effectivenes...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...

Successful Trials of AstraZeneca’s Cancer and Anemia Drugs

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials. The positive results provide a shot in the arm for the c...

Pyramid Biosciences Entered into Exclusive Licensing Agreement with AstraZeneca

Pyramid Biosciences, Inc., a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an exclusive, worldwide...

AstraZeneca and AVEO to investigate Liver Cancer Immunotherapy

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer. AZ’s Imfinzi (durvalumab) immunotherapy has suff...

MMCC aims to catalyze transformational Change in Microbiology Testing

Attending Pharmig 2018, AstraZeneca's Karen Capper and GSK's Paul J Newby unveiled details of the Microbiology Modernisation Cross-industry Consortium (MMCC), an initiative that has been in the making...

Cancer Research UK and AstraZeneca to create a functional genomics centre

cancer treatment
Cancer Research UK and AstraZeneca announced the opening of a new centre, dedicated to realizing the full potential of functional genomics in the discovery and development of cancer drugs.

Five Russian startups present their projects at Cambridge Biomedical Campus

The winners of the Startup Challenge accelerator, organised jointly by the Skolkovo Foundation and AstraZeneca, are showcasing their inventions at the International Future Healthcare Forum.

AstraZeneca sells its rights for three corticosteroid drugs to Covis Pharma

AstraZeneca has entered into an agreement with Covis Pharma B.V. (Switzerland) to sell its rights to the medicines Alvesco (ciclesonide), and Omnaris and Zetonna (ciclesonide).

Grünenthal signs $922 million deal with AstraZeneca

Grünenthal announced that it has agreed to acquire AstraZeneca's European rights to Nexium and the global rights to Vimovo for a total consideration of up to $922 million (€ 811 million).

AstraZeneca signs new agreement with Innate Pharma

AstraZeneca announced a new multi-term agreement with Innate Pharma, building on an existing collaboration, aimed at accelerating each company’s oncology portfolio.